Back to top
more

Cullinan Therapeutics, Inc. (CGEM)

(Delayed Data from NSDQ)

$23.17 USD

23.17
827,363

-0.64 (-2.69%)

Updated May 17, 2024 04:00 PM ET

After-Market: $23.12 -0.05 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CGEM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

9 items in cart

View Cart/Checkout

Cullinan Therapeutics, Inc. [CGEM]

Reports for Purchase

Showing records 21 - 40 ( 46 total )

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

03/27/2023

Daily Note

Pages: 3

Cullinan Announces IND Clearance For CLN-617

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

03/10/2023

Company Report

Pages: 8

4Q22 Results; Six Products Expected to Be in Clinical Development by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

02/14/2023

Company Report

Pages: 8

CLN-418 Gives Cullinan Another Shot on Goal

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

01/24/2023

Daily Note

Pages: 3

Cullinan Announces IND-Clearance for CLN-978

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

11/15/2022

Company Report

Pages: 8

3Q22 Results; Pivotal Study for Zipalertinib (CLN-081) Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

10/25/2022

Company Report

Pages: 7

Cullinan Raises Ownership Level in Cullinan MICA Subsidiary

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

08/11/2022

Company Report

Pages: 8

2Q22 Results; Initiation of Pivotal Study for CLN-081 Planned for 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

06/23/2022

Daily Note

Pages: 3

Completion of CLN-081 Strategic Collaboration Agreement With Taiho Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

05/31/2022

Daily Note

Pages: 3

Updated Data for CLN-081 in NSCLC Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

05/17/2022

Company Report

Pages: 8

1Q22 Results; Sale of Cullinan Pearl; Initial Clinical Data for CLN-049 and CLN-619 Expected Mid-2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

05/12/2022

Company Report

Pages: 8

Strategic Collaboration With Taiho Pharmaceutical For Joint Development and Commercialization of CLN-081

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/29/2022

Company Report

Pages: 8

CLN-081 Clinical and Regulatory Update Webinar; CLN-081 Pivotal Trial Expected to Start 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

01/04/2022

Daily Note

Pages: 3

CLN-081 Granted BTD for NSCLC Patients With EGFR Exon 20 Insertion Mutations That Received Prior Platinum Chemo

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

12/16/2021

Company Report

Pages: 8

Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients; 100mg BID Nominated as RP2D

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

11/10/2021

Company Report

Pages: 8

3Q21 Results; Focus Remains on the CLN-081 Update Expected Before Year End

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

10/18/2021

Daily Note

Pages: 3

Management Change; Nadim Ahmed Appointed as CEO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CGEM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

08/11/2021

Company Report

Pages: 8

2Q21 Results; CLN-081 Clinical and Regulatory Updates Expected in 4Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

06/29/2021

Daily Note

Pages: 3

FDA Clears IND Application for CLN-619

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Cullinan Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

06/07/2021

Daily Note

Pages: 3

IND Application for CLN-049 Cleared by FDA

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party